Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 20/20 | 0.64 |
| ▸ | CTSS | P25774 | 9/20 | 0.61 |
| ▸ | CTSL | P07711 | 7/20 | 0.61 |
| ▸ | CTSV | O60911 | 2/20 | 0.49 |
| ▸ | CTSB | P07858 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1479714 | 1.00 | CTSK (0.64) | CTSKCTSSCTSLCTSVCTSB | |
| SCHEMBL16930866 | 1.00 | CTSK (0.64) | CTSKCTSSCTSLCTSVCTSB | |
| SCHEMBL1482400 | 0.99 | CTSK (0.64) | CTSKCTSSCTSLCTSVCTSB | |
| SCHEMBL1480003 | 0.99 | CTSK (0.64) | CTSKCTSSCTSLCTSVCTSB | |
| SCHEMBL3545774 | 0.92 | CTSK (0.64) | CTSKCTSSCTSLCTSVCTSB | |
| SCHEMBL1482439 | 0.92 | CTSK (0.75) | CTSKCTSSCTSL | |
| SCHEMBL3543820 | 0.92 | CTSK (0.65) | CTSKCTSSCTSLCTSVCTSB | |
| SCHEMBL3543908 | 0.92 | CTSK (0.65) | CTSKCTSSCTSLCTSVCTSB | |
| SCHEMBL3546036 | 0.92 | CTSK (0.65) | CTSKCTSSCTSLCTSVCTSB | |
| SCHEMBL1480676 | 0.92 | CTSK (0.75) | CTSKCTSSCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2240491-B1 | TETRAHYDROFURO(2,3-b)PYRROL-3-ONE DERIVATIVES AS INHIBITORS OF CYSTEINE PROTEINASES | AMURA THERAPEUTICS LTD (GB) | 2015-07-15 | — | — | EP | claimed |
| EP-2719700-A1 | TETRAHYDROFURO(3,2-B)PYRROL-3-ONE DERIVATIVES AS INHIBITORS OF CYSTEINE PROTEINASES | Amura Therapeutics Limited (GB) | 2014-04-16 | — | — | EP | claimed |
| US-20130252969-A1 | Compounds | AMURA THERAPEUTICS LIMITED (GB) | 2013-09-26 | — | — | US | claimed |
| US-20110077254-A1 | COMPOUNDS | AMURA THERAPEUTICS LIMITED (GB) | 2011-03-31 | — | — | US | claimed |
| EP-2240491-B1 | TETRAHYDROFURO(2,3-b)PYRROL-3-ONE DERIVATIVES AS INHIBITORS OF CYSTEINE PROTEINASES | AMURA THERAPEUTICS LTD (GB) | 2015-07-15 | — | — | EP | disclosed |
| US-9045492-B2 | Piperazine compounds | AMURA THERAPEUTICS LIMITED (GB) | 2015-06-02 | — | — | US | disclosed |
| EP-2719700-A1 | TETRAHYDROFURO(3,2-B)PYRROL-3-ONE DERIVATIVES AS INHIBITORS OF CYSTEINE PROTEINASES | Amura Therapeutics Limited (GB) | 2014-04-16 | — | — | EP | disclosed |
| US-20130252969-A1 | Compounds | AMURA THERAPEUTICS LIMITED (GB) | 2013-09-26 | — | — | US | disclosed |
| US-8501744-B2 | Piperazine compounds | AMURA THERAPEUTICS, LIMITED (GB) | 2013-08-06 | — | — | US | disclosed |
| US-20110077254-A1 | COMPOUNDS | AMURA THERAPEUTICS LIMITED (GB) | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077254-A1 | COMPOUNDS | CHRM1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PRMT9 | CTSK 4062/4885CTSS 3917/4885CTSL 2955/4885 |
| US-20130252969-A1 | Compounds | CHRM1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PRMT9 | CTSK 4066/4885CTSS 3908/4885CTSL 2921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.